PD-1/PD-L1信号通路与慢性乙型肝炎*

doi:10.3969/j.issn.1672-5069.2014.06.028

Abstract

Abstract: Programmed death-1（PD-1） is an important coordinated stimulus molecule belonging to the B7/CD28 family. When it combines with its ligand programmed death ligand （PD-L）,can regulate the activation,differentiation and multiplication of T lymphocytes. PD-1 expression in different stages of chronic HBV infection varies,and is closely related to the degree of liver inflammation,ALT levels and viral loads. Through different ways to block the PD-1/PD-L1 pathway can improve the function of T lymphocytes,and it might be one of the direction for antiretroviral treatment in the future.

Key words: Hepatitis B, Programmed death-1, Programmed death -1 ligand, T lymphocytes

Wan Hehe, Liu Lili, Hou Yong, Zhang Guoliang. PD-1/PD-L signal pathway in chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 661-665.

References

[1] Chen GC,Yu T,Huang KH,et al. Antiviral therapy of decompensated hepatitis B virus-related cirrhosis. Chin Med J,2012,125（2）:373-377.
[2] Li XD,Wang L,Liu Y,et al. Characterization of hepatitis B virus genotypes/subgenotypes in 1301 patients with chronic hepatitis B in North China. Chin Med J,2011,124（24）:4178-4183.
[3] Lok AS,McMahon BJ. Chronic hepatitis B. Hepatology,2007,45（2）:507-539.
[4] Yao S,Chen L. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends Mol Med,2006,12（6）:244-246.
[5] Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol,2004,4（5）:336-347.
[6] Ishida Y,Agata Y,Shibahara K,et al. Induced expression of PD1,a novel member of the immunoglobulin gene superfamily upon programmed cell death. EMBO J,1992,11（11）:3887-3895.
[7] Greenwald RJ,Freeman GJ,Sharpe AH. The B7 family revisited. Annu Rev Immunol,2005,23:515-548.
[8] Bennett F,Luxenberg D,Ling V,et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation:attenuation of ICOS,IL-4,and IL-21,but not CD28,IL-7,and IL-15 responses. J Immunol,2003,170（2）:711-718.
[9] Okazaki T,Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol,2006,27（4）:195-201.
[10] Wherry EJ,Ha SJ,Kaech SM,et al. Molecular signature of CD8 + T cell exhaustion during chronic viral infection. Immunity,2007,27（4）:670-684.
[11] Boni C,Fisicaro P,Valdatta C,et al. Characterization of hepatitis B virus （HBV）-specific T-cell dysfunction in chronic HBV infection. J Virol,2007,81（8）: 4215-4225.
[12] Nishimura H,Honjo T,Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-l-deficient mice. J Exp Med,2000,191（5）:891-898.
[13] Zhang X,Schwartz JC,Guo XL,et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity,2004,20（3）:337-347.
[14] Yang W,Li H,Chen PW,et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthmol Vis Sci,2009,50（1）:273-280.
[15] Fife BT,Pauken KE. The role of the PD1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci,2011,1217:45-59.
[16] Sugita S,Usui Y,Horie S,et al. Human corneal endothelial cells expressing programmed death-ligand l（PD-Ll） suppress PD-l+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci,2009,50（l）:263-272.
[17] Margarite L,Tarrio N,Grabie N,et al. PD-1 protects against inflammation and lymphocyte damage in T cell mediated myocarditis. J Immunol,2012,188（10）:4876-4884.
[18] Liang SC,Latchman YE,Buhlmann JE,et al. Regulation of PD-1,PD-L1 and PD-L2 expression during normal and autoimmune responses. Eur J Immunol,2003,33（10）:2706-2716.
[19] Ishida M,Iwai Y,Tanaka Y,et al. Differential expression of PD-L1 and PD-L2,ligands for an inhibitory receptor PD-1,in the cells of lymphohematopoietic tissues. Immunol Lett,2002,84（1）:57-62.
[20] Martinic MM,Von Herrath MG. Novel strategies to eliminate persistent viral infections. Trends Immunol,2008,29（3）:116-124.
[21] Sakuishi K,Apetoh L,Sullivan JM,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med,2010,207（10）:2187-2194.
[22] Baecher-Allan C,Brown JA,Freeman GJ,et al. CD4 + CD25 + regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp,2003,252:67-68.
[23] Grzywnowicz M,Zaleska J,Mertens D,et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One,2012,7（4）:e35178.
[24] Tamura H,Dong HD,Zhu GF. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood,2001,97（6）:1809-1816.
[25] Zhang Z,Jin B,Zhang JY,et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol,2009,50:1163-1173.
[26] Ye P,Weng ZH,Zhang SL,et al. Programmed death-1 expression is associated with the disease status in hepatitis B virus infection. World J Gastroenterol,2008,14:4551-4557.
[27] Peng G,Li S,Wu W,et al. PD-1 upregulation is associated with HBV- specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol,2008,45（4）:963-970.
[28] Fisicaro P,Valdatta C,Massari M,et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology,2010,138（2）:682-693.
[29] 梁雪松,李成忠,万漠彬,等. 外周血T细胞表面PD-1在慢性乙型肝炎患者干扰素治疗期间的表达. 世界华人消化杂志,2009,17:2899-2902.
[30] Zhang WJ,Peng CH,Zheng SS. Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int,2013,12（4）:394-399.
[31] Liang XS,Zhou Y,Li CZ,et al. Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells. World J Gastroenterol,2010,16（5）:618-624.
[32] 李新慧,夏娟,许林,等. 慢性乙型肝炎患者不同免疫状态下外周血T细胞表面程序性死亡受体1的表达. 江苏医药,2011,7（12）:1423-1426.
[33] Tzeng HT,Tsai HF,Liao HJ,et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model[J/OA]. PLoS One,2012,7（6）:e39179.
[34] Xie Z,Chen Y,Zhao S,et al. Intrahepatic PD-1/PD-Ll up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest,2009,38（7）:624-638.
[35] Georgios G,Nikoletta A,Prodromos H,et al. Liver FOXP3 and PD1/PDL1 expression is down-regulated in chronic HBV hepatitis on maintained remission related to the degree of inflammation. Frontiers in Immunol,2013,4:1-9.dol:10.3389/fimmu.2013.00207.
[36] Ping X,Yong JC,Hui C,et al. The expression of programmed death-1 in circulating CD4 + and CD8 + T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver,2014,8（2）:186-195.
[37] 谢冬英,陈凤娟,林炳亮,等. PD-1和PD-L1表达与慢性HBV感染者肝脏病变程度的相关性. 中华实验和临床感染病杂志:电子版,2010,4（3）:287-293.
[38] 叶翩,翁志宏,张淑玲,等.慢性乙型肝炎患者外周血CD8+T淋巴细胞表面程序性死亡受体-1表达上调的意义.中华肝脏病杂志,2008,16 （9）:706-707.
[39] Ghiotto M,Gauthier L,Serriari N,et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol,2010,22（8）: 651-660.
[40] Evans A,Riva A,Cooksley H,et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B:Impact of hepatitis B e-antigen seroconversion. Hepatology,2008,48:759-769.
[41] Bowen DG,Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature,2005,436:946-952.
[42] Chen LG,Zhang Z,Chen WW,et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol,2007,178 （10）:6634.
[43] Maier H,Isogawa M,Freeman GJ,et al. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol,2007,178（5）:2714-2720.

PD-1/PD-L signal pathway in chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.